Amylyx (AMLX) announced that the FDA has granted fast track designation to AMX0114, an investigational antisense oligonucleotide targeting calpain-2 for the treatment of people living with amyotrophic lateral sclerosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx initiated with a Buy at TD Cowen
- Amylyx price target raised to $8 from $7 at Mizuho
- Positive Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising HELIOS Trial Results for AMX0035
- Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges
- Amylyx announces results from Phase 2 HELIOS trial of AMX0035